Projects
View
| Name | AMYPAD |
|---|---|
| Long Name | Amyloid imaging to prevent Alzheimer’s disease |
| Description | Amyloid imaging to prevent Alzheimer’s disease. Deposits of beta amyloid protein in the brain are a common sign of Alzheimer’s disease. AMYPAD will study the value of using positron emission tomography (PET) imaging to scan people’s brains for beta amyloid deposits. AMYPAD will carry out beta amyloid PET imaging on an unprecedented number of people who are suspected to be in the early stages of Alzheimer’s disease. The goal is to determine the clinical added value of PET imaging in diagnosis and patient monitoring, and to develop data to establish its usefulness in clinical trials. AMYPAD will work closely with IMI’s EPAD project, which is working to increase our understanding of the early stages of dementia and creating a platform to test treatments designed to prevent dementia. |
| Objectives | 1. Improve the diagnostic workup of patients suspected to have AD (3) and their management. 2. Understand the natural history of AD in a pre‐symptomatic stage in order to better select patients for trials. 3. Monitor change in β‐amyloid deposition to quantify the impact of novel therapies. |
| Website | https://amypad.eu/ |
| Start date | 01-10-2016 |
| End date | 30-09-2022 |
| Logo |  |
| Name | Projects | Type of institution | Country | |
|---|---|---|---|---|
| Synapse Research Management Partners SL | EPAD AMYPAD NEURONET EMIF ROADMAP | SME | Spain | |
| University Of Edinburgh | EPAD AMYPAD EQIPD ROADMAP | Academia | United Kingdom | |
| Janssen Pharmaceutica NV | EPAD ADAPTED AMYPAD IMPRiND EQIPD NEURONET EMIF IM2PACT PHAGO PRISM RADAR-CNS RADAR-AD ROADMAP IDEA-FAST Pharma-Cog EPND | EFPIA | Belgium | |
| Alzheimer Europe | EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD ROADMAP NEURONET Pharma-Cog EPND | Patient/carers organisation | Luxembourg | |
| Fundacio Barcelonabeta Brain Research Center | EPAD AMYPAD AETIONOMY | Academia | Spain | |
| VU University Medical Center Amsterdam | EPAD AMYPAD IM2PACT PRISM MOPEAD RADAR-CNS RADAR-AD EMIF PRISM2 Pharma-Cog EPND | Academia | Netherlands | |
| Karolinska Institutet | EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD | Academia | Sweden | |
| Klinikum Der Universitaet Zu Koeln | EPAD AMYPAD MOPEAD ADAPTED | Academia | Germany | |
| Universite De Geneve | EPAD AMYPAD EPND | Academia | Switzerland | |
| Centre Hospitalier Universitaire De Toulouse | EPAD AMYPAD | Academia | France | |
| University College London | AMYPAD PD-MitoQUANT PHAGO EMIF | Academia | United Kingdom | |
| IXICO Technologies LTD | AMYPAD ROADMAP EPAD | SME | United Kingdom | |
| Life Molecular Imaging LTD | AMYPAD | Other | United Kingdom | |
| GE healthcare Ltd | AMYPAD ROADMAP | EFPIA | United Kingdom | |
| Stichting Katholieke Universiteit / Radboud University Nijmegen Medical Centre | EPAD EQIPD PRISM AMYPAD PD-MitoQUANT PRISM2 | Academia | Netherlands |
| WP number | Description | Project | |
|---|---|---|---|
| WP1 | Overall project governance and management | AMYPAD | |
| WP2 | Tracer delivery, PET scanning and Image analysis | AMYPAD | |
| WP3 | Diagnostic and Patient Management Study | AMYPAD | |
| WP4 | Risk stratification: Natural history and enrichment strategies | AMYPAD | |
| WP5 | Monitoring treatment: Quantifying patient-specific efficacy | AMYPAD | |
| WP6 | Ethics, communication and dissemination | AMYPAD |
| Deliverable number | Title | Project | Submission date | Link | Keywords | |
|---|---|---|---|---|---|---|
| D1.2 | Project Handbook, including the internal communication tools | AMYPAD | 09-04-2019 | https://amypad.eu/wp-content/uploads/2017/04/D1.2-AMYPAD.pdf | ||
| D2.1 | Tracer strategy & Site Selection | AMYPAD | 01-01-2017 | https://amypad.eu/wp-content/uploads/2016/12/D2.1-AMYPAD.pdf | ||
| D1.1 | Report on AMYPAD governance and relationship with EPAD | AMYPAD | 01-02-2017 | https://amypad.eu/wp-content/uploads/2017/01/D1.1-AMYPAD.pdf | ||
| D6.1 | Initial communication Plan, including project branding and policies | AMYPAD | 01-03-2017 | https://amypad.eu/wp-content/uploads/2017/03/D6.1-AMYPAD-1.pdf | ||
| D3.1 | Report on feedback from EMA on design of diagnostic study | AMYPAD | 01-04-2017 | https://amypad.eu/wp-content/uploads/2017/04/D3.1-AMYPAD.pdf | ||
| D2.4 | Image database and SUVR quantification methods implemented | AMYPAD | 01-04-2017 | https://amypad.eu/wp-content/uploads/2017/04/D2.4-AMYPAD.pdf | ||
| D2.3 | Operating Process Document (methodology and processes) | AMYPAD | 01-04-2017 | https://amypad.eu/wp-content/uploads/2017/04/D2.3-AMYPAD.pdf | ||
| D2.2 | Clinical Imaging network set up & sites certified | AMYPAD | 11-11-2020 | https://amypad.eu/wp-content/uploads/2017/04/D2.2-AMYPAD.pdf | ||
| D1.3 | Initial Data & Knowledge Management Plan | AMYPAD | 01-04-2017 | https://amypad.eu/wp-content/uploads/2017/04/D1.3-AMYPAD.pdf | ||
| D6.3 | Initial report on Dissemination tools | AMYPAD | 11-11-2020 | https://amypad.eu/wp-content/uploads/2017/09/D6.3-AMYPAD.pdf | ||
| D4.1 | Set-up of the EPAD/AMYPAD Collaboration Framework | AMYPAD | 01-09-2017 | https://amypad.eu/wp-content/uploads/2017/10/D4.1-AMYPAD.pdf | ||
| D6.2 | Ethics Policy and Guidance Document | AMYPAD | 01-10-2017 | https://amypad.eu/wp-content/uploads/2017/10/D6.2-AMYPAD.pdf | ||
| D3.2 | First study subject approval package | AMYPAD | 01-10-2017 | https://amypad.eu/wp-content/uploads/2017/10/D3.2-AMYPAD.pdf | ||
| D6.4 | Report on public access policies | AMYPAD | 01-10-2017 | https://amypad.eu/wp-content/uploads/2017/10/D6.4-AMYPAD.pdf | ||
| D5.1 | Collection of existing data and development of analysis strategy | AMYPAD | 11-11-2020 | https://amypad.eu/wp-content/uploads/2017/10/D5.1-AMYPAD.pdf | ||
| D4.2 | EPAD/AMYPAD Protocol with regulatory approval | AMYPAD | 01-10-2017 | https://amypad.eu/wp-content/uploads/2017/10/D4.2-AMYPAD.pdf | ||
| D3.3 | Amyloid PET quantification protocol and imaging charter | AMYPAD | 01-04-2018 | https://amypad.eu/wp-content/uploads/2018/04/D3.3-AMYPAD.pdf | ||
| D2.5 | Online platform for data sharing | AMYPAD | 01-04-2018 | https://amypad.eu/wp-content/uploads/2018/04/D2.5-AMYPAD.pdf | ||
| D4.3 | Site selection from EPAD network complete | AMYPAD | 01-07-2018 | https://amypad.eu/wp-content/uploads/2018/07/D4.3-AMYPAD.pdf | ||
| D6.6 | Report from the Ethics Advisory - AMYPAD Year 1 | AMYPAD | 01-07-2018 | https://amypad.eu/wp-content/uploads/2020/01/D6.6-AMYPAD.pdf | ||
| D6.7 | Report from the Ethics Advisory - AMYPAD Year 2 | AMYPAD | 01-11-2018 | https://amypad.eu/wp-content/uploads/2020/01/D6.7-AMYPAD.pdf | ||
| D5.3 | Interim report on basic disease modelling | AMYPAD | 01-02-2019 | https://amypad.eu/wp-content/uploads/2019/02/D5.3-AMYPAD.pdf | ||
| D6.5 | Initial Report on dissemination activities and communication strategy update | AMYPAD | 11-11-2020 | https://amypad.eu/wp-content/uploads/2019/04/D6.5-AMYPAD.pdf | ||
| D4.7 | Mid-term Recruitment Report (Month 30) Quarterly report V1.0 | AMYPAD | 11-11-2020 | https://amypad.eu/wp-content/uploads/2019/07/D4.7-AMYPAD.pdf | ||
| D3.6 | Mid-term Recruitment Report (Month 30) | AMYPAD | 01-04-2019 | https://amypad.eu/wp-content/uploads/2019/07/D3.6-AMYPAD.pdf | ||
| D1.4 | Interim report on project progress | AMYPAD | 01-04-2019 | https://amypad.eu/wp-content/uploads/2019/04/D1.4-AMYPAD.pdf | ||
| D4.4 | Mid-term Recruitment Report | AMYPAD | 01-07-2019 | https://amypad.eu/wp-content/uploads/2019/07/D4.4-AMYPAD.pdf | ||
| D5.2 | Report on the preliminary Scientific Advice from regulatory bodies | AMYPAD | 01-07-2019 | https://amypad.eu/wp-content/uploads/2019/11/D5.2-AMYPAD.pdf | ||
| D3.4 | Mid-term Recruitment Report | AMYPAD | 01-07-2019 | https://amypad.eu/wp-content/uploads/2019/07/D3.4-AMYPAD.pdf | ||
| D4.8 | Report on selection criteria for repeat imaging | AMYPAD | 01-10-2019 | https://amypad.eu/wp-content/uploads/2019/11/D4.8-AMYPAD.pdf | ||
| D4.6 | All approval packages | AMYPAD | 01-10-2019 | https://amypad.eu/wp-content/uploads/2019/11/D4.6-AMYPAD.pdf | ||
| D4.5 | Mid-term Recruitment Report | AMYPAD | 01-10-2019 | https://amypad.eu/wp-content/uploads/2019/11/D4.5-AMYPAD.pdf | ||
| D3.8 | All approvals package | AMYPAD | 01-10-2019 | https://amypad.eu/wp-content/uploads/2019/11/D3.8-AMYPAD.pdf | ||
| D3.7 | Disclosure of amyloid PET results to persons with subjective cognitive decline - an AMYPAD sub-study | AMYPAD | 01-10-2019 | https://amypad.eu/wp-content/uploads/2019/11/D3.7-AMYPAD.pdf | ||
| D3.5 | Mid-term Recruitment Report | AMYPAD | 01-10-2019 | https://amypad.eu/wp-content/uploads/2019/11/D3.5-AMYPAD.pdf | ||
| D1.5 | Interim Data & Knowledge Management Plan | AMYPAD | 01-10-2019 | https://amypad.eu/wp-content/uploads/2019/11/D1.5-AMYPAD.pdf | ||
| D6.8 | Report from the Ethics Advisory - AMYPAD Year 3 | AMYPAD | 01-11-2019 | https://amypad.eu/wp-content/uploads/2020/01/D6.8-AMYPAD.pdf | ||
| D3.9 | Mid-term recruitment report | AMYPAD | 01-01-2020 | https://amypad.eu/wp-content/uploads/2020/01/D3.9-AMYPAD.pdf | ||
| D2.6 | Descriptive Report on amyloid PET scan quantification I | AMYPAD | 01-01-2020 | https://amypad.eu/wp-content/uploads/2020/01/D2.6-AMYPAD.pdf | ||
| D4.9 | Mid-term recruitment report | AMYPAD | 01-01-2020 | https://amypad.eu/wp-content/uploads/2020/01/D4.9-AMYPAD.pdf | ||
| D3.11 | Mid-term recruitment report Quarterly report V5 | AMYPAD | 01-03-2020 | https://amypad.eu/wp-content/uploads/2020/03/D3.11-AMYPAD.pdf | ||
| D5.4 | Interim report on advanced disease modelling | AMYPAD | 01-04-2020 | https://amypad.eu/wp-content/uploads/2020/04/D5.4-AMYPAD.pdf | ||
| D3.10 | Baseline clinical and amyloid-PET features (M42) | AMYPAD | 01-04-2020 | https://amypad.eu/wp-content/uploads/2020/04/D3.10-AMYPAD.pdf | ||
| D4.11 | Mid-term Recruitment Report V6 | AMYPAD | 01-07-2020 | https://amypad.eu/wp-content/uploads/2020/07/D4.11-AMYPAD.pdf | ||
| D3.12 | Mid-term recruitment report Quarterly report V6 | AMYPAD | 01-07-2020 | https://amypad.eu/wp-content/uploads/2020/07/D3.12-AMYPAD.pdf | ||
| D3.13 | Mid-term Recruitment Report | AMYPAD | 01-10-2020 | https://amypad.eu/wp-content/uploads/2020/10/D3.13-AMYPAD.pdf | ||
| D4.12 | Mid-term Recruitment Report | AMYPAD | 01-10-2020 | https://amypad.eu/wp-content/uploads/2020/10/D4.12-AMYPAD.pdf | ||
| D4.13 | Disease modelling report v1 | AMYPAD | 01-10-2020 | https://amypad.eu/wp-content/uploads/2020/10/D4.13-AMYPAD.pdf | ||
| D4.14 | Integration of non-EPAD cohorts | AMYPAD | 01-10-2020 | https://amypad.eu/wp-content/uploads/2020/10/D4.14-AMYPAD.pdf | ||
| D1.6 | Project assessment | AMYPAD | 01-11-2020 | https://amypad.eu/wp-content/uploads/2020/11/D1.6-AMYPAD.pdf | ||
| D2.7 | Descriptive Report of Amyloid PET Scan Quantification II | AMYPAD | 30-11-2020 | https://amypad.eu/wp-content/uploads/2020/11/D2.7-AMYPAD.pdf | amyloid, quantification, data, cerebellum, csf, biomarkers, patient, analysis, imaging, | |
| D6.9 | Report from the Ethics Advisory - AMYPAD Year 4 | AMYPAD | 01-11-2020 | https://amypad.eu/wp-content/uploads/2021/11/D6.9-AMYPAD.pdf | ||
| D4.15 | Mid-term Recruitment Report V8 | AMYPAD | 01-02-2021 | https://amypad.eu/wp-content/uploads/2021/02/D4.15-AMYPAD.pdf | ||
| D3.15 | Mid-term recruitment report Quarterly report V8 | AMYPAD | 07-07-2022 | https://amypad.eu/wp-content/uploads/2021/02/D3.15-AMYPAD.pdf | ||
| D4.16 | Mid-term Recruitment Report V9 | AMYPAD | 01-04-2021 | https://amypad.eu/wp-content/uploads/2021/04/D4.16-AMYPAD.pdf | ||
| D3.16 | Mid-term recruitment report Quarterly report V9 | AMYPAD | 01-04-2021 | https://amypad.eu/wp-content/uploads/2021/05/D3.16-AMYPAD.pdf | ||
| D4.17 | Mid-term recruitment report V10 | AMYPAD | 01-08-2021 | https://amypad.eu/wp-content/uploads/2021/08/D4.17-AMYPAD.pdf | ||
| D3.17 | Mid-term recruitment report Quarterly report V10 | AMYPAD | 29-08-2021 | https://amypad.eu/wp-content/uploads/2021/08/D3.17-AMYPAD.pdf | ||
| D6.10 | Report on the perspective of research participants on disclosing amyloid PET imaging biomarkers | AMYPAD | 29-10-2021 | https://amypad.eu/wp-content/uploads/2021/10/D6.10-AMYPAD.pdf | ||
| D6.12 | Final report on ethics | AMYPAD | 29-10-2021 | https://amypad.eu/wp-content/uploads/2021/10/D6.12-AMYPAD.pdf | ||
| D4.21 | Mid-term Recruitment Report V11 | AMYPAD | 29-10-2021 | https://amypad.eu/wp-content/uploads/2021/10/D4.21-AMYPAD.pdf | ||
| D6.13 | Report from the Ethics Advisory - AMYPAD Year 5 | AMYPAD | 29-11-2021 | https://amypad.eu/wp-content/uploads/2021/11/D6.13-AMYPAD.pdf | ||
| D3.18 | Final Report on Recruitment (DPMS) | AMYPAD | 29-11-2021 | https://amypad.eu/wp-content/uploads/2021/11/D3.18-AMYPAD.pdf | ||
| D2.8 | Descriptive Report of Amyloid PET Scan Quantification III | AMYPAD | 29-12-2021 | https://amypad.eu/wp-content/uploads/2021/12/D2.8-AMYPAD.pdf | ||
| D4.22 | Mid-term Recruitment Report V12 | AMYPAD | 29-01-2022 | https://amypad.eu/wp-content/uploads/2022/01/D4.22-AMYPAD.pdf | ||
| D3.19 | Impact of amyloid PET on diagnosis, treatment, and adverse health outcomes | AMYPAD | 06-07-2022 | https://amypad.eu/wp-content/uploads/2022/03/D3.19-AMYPAD.pdf | ||
| D4.23 | Mid-term Recruitment Report V13 | AMYPAD | 29-04-2022 | https://amypad.eu/wp-content/uploads/2022/04/D4.23-AMYPAD.pdf |
| Title | First author last name | Year | Project | Link | Keywords | |
|---|---|---|---|---|---|---|
| Faster PET reconstruction with a stochastic primal-dual hybrid gradient method | Ehrhardt | 2017 | AMYPAD | https://doi.org/10.1117/12.2272946 | Conference proceedings, brain imaging, Positron emission tomography, Inverse problems, Optimization (mathematics), Reconstruction algorithms, Convex optimization | |
| NiftyPET: a High-throughput Software Platform for High Quantitative Accuracy and Precision PET Imaging and Analysis | Markiewicz | 2018 | AMYPAD | http://dx.doi.org/10.1007/s12021-017-9352-y | Informatics research paper, PET, quantification, Image reconstruction, uncertainty, bootstrap, scatter correction, random events estimation, partial volume correction, normalisation | |
| The Rationale Behind the New Alzheimer’s Disease Conceptualization: Lessons Learned During the Last Decades | Molinuevo | 2018 | AMYPAD | http://dx.doi.org/10.3233/JAD-170698 | Review article, Alzheimer’s disease, biomarkers, continuum, ethical challenges, preclinical, prevention | |
| Assessing Amyloid Pathology in Cognitively Normal Subjects using [18F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods | Collij | 2018 | AMYPAD | http://dx.doi.org/10.2967/jnumed.118.211532 | Clinical research paper, 18F-flutemetamol PET, amyloid pathology, visual assessment, preclinical Alzheimer disease | |
| AMYPAD Diagnostic and Patient Management Study: Rationale and design | Frisoni | 2018 | AMYPAD | http://dx.doi.org/10.1016/j.jalz.2018.09.003 | Clinical study protocol, PET, amyloid, brain imaging, cognitive decline, Alzheimer's disease | |
| Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies | Heeman | 2019 | AMYPAD | https://doi.org/10.1186/s13550-019-0499-4 | Clinical research paper, amyloid, quantification, simplified methods, flutemetamol PET, florbetaben PET, Alzheimer’s disease | |
| IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease | Frisoni | 2019 | AMYPAD | https://doi.org/10.1016/S1474-4422(19)30166-8 | Opinion paper, PET, amyloid, Alzheimer's disease, tau | |
| Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease | Archetti | 2019 | AMYPAD | https://doi.org/10.1016/j.nicl.2019.101954 | Clinical research paper, Alzheimer's disease, event-based models, inter-cohort validation, biomarkers progression, patient staging | |
| Simulating the effect of cerebral blood flow changes on regional quantification of [18F]flutemetamol and [18F]florbetaben studies | Heeman | 2020 | AMYPAD | https://doi.org/10.1177/0271678X20918029 | Clinical research paper, Alzheimer’s disease, amyloid PET, cerebral blood flow, quantification, simulation study | |
| Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study | Lopes Alves | 2020 | AMYPAD | https://doi.org/10.1002/alz.12069 | Clinical research paper, alzheimer's disease, PET, amyloid, clinical trial | |
| The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging | Fantoni | 2019 | AMYPAD | http://jnm.snmjournals.org/content/61/2/166 | amyloid PET, staging, spatial-temporal ordering, pathology | |
| Multitracer model for staging cortical amyloid deposition using PET imaging | Collij | 2020 | AMYPAD | https://doi.org/10.1212/WNL.0000000000010256 | PET imaging, Amyloid, Alzheimer’s disease, Staging, Cognition | |
| [11C]PIB amyloid quantification: effect of reference region selection | Heeman | 2020 | AMYPAD | https://doi.org/10.1186/s13550-020-00714-1 | [11C]PiB, Alzheimer’s disease, Amyloid PET, Quantification, Reference regions | |
| The Framing of “Alzheimer’s Disease”: Differences Between Scientific and Lay Literature and Their Ethical Implications | Smedinga | 2020 | AMYPAD | https://doi.org/10.1093/geront/gnaa113 | Biomarkers, Dementia, Ethics, Framing analysis, Metaphor | |
| Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias | Chetelat | 2020 | AMYPAD | https://doi.org/10.1016/S1474-4422(20)30314-8 | biomarkers, amyloid, diagnostic | |
| The effects of age on resting-state BOLD signal variability is explained by cardiovascular and cerebrovascular factors | Tsvetanov | 2020 | AMYPAD | https://doi.org/10.1111/psyp.13714 | aging, cerebral vascular reactivity, functional magnetic resonance imaging (fMRI), individual differences. | |
| Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients | Boccardi | 2020 | AMYPAD | https://doi.org/10.1111/ene.14117 | Alzheimer’s disease, MCI, biomarker, biomarker-based diagnosis, consensus recommendations, diagnosis, diagnostic algorithm. implementation. multiple biomarkers | |
| The characterisation of subjective cognitive decline | Jessen | 2020 | AMYPAD | https://doi.org/10.1016/s1474-4422(19)30368-0 | Review article, clinical research, subjective cognitive decline, Alzheimer's disease, neurodegeneration | |
| Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity | Sala | 2020 | AMYPAD | https://doi.org/10.1038/s41380-020-00950-w | csf, biomarkers, pet, baseline, alzheimer, accumulation, pathology, biomarker, disease, brain | |
| Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease‐modifying therapies | Frisoni | 2020 | AMYPAD | https://doi.org/10.1002/alz.12132 | ||
| Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging | Markiewicz | 2021 | AMYPAD | https://www.sciencedirect.com/science/article/pii/S1053811921000987 | PET, MR, Registration, Precision, Partial volume correction, Amyloid, Alzheimer’s disease | |
| Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent | Collij | 2021 | AMYPAD | https://doi.org/10.1007/s00259-020-05174-2 | Amyloid PET, [18F]flutemetamol, Regional visual read, Centiloid, Sensitivity, Neuropathology | |
| Early detection of amyloid load using 18 F-florbetaben PET | Bullich | 2021 | AMYPAD | https://doi.org/10.1186/s13195-021-00807-6 | Alzheimer’s disease; Amyloid-beta; Florbetaben; Mild cognitive impairment; PET; Subjective memory complainers. | |
| Parametric imaging of dual-time window [18F] flutemetamol and [18F] florbetaben studies | Heeman | 2021 | AMYPAD | https://doi.org/10.1016/j.neuroimage.2021.117953 | Amyloid PET, [18F]flutemetamol, [18F]florbetaben, Parametric imaging, PET quantification | |
| Diagnostic value of amyloid-PET and tau-PET a head-to-head comparison | Altomare | 2021 | AMYPAD | https://doi.org/10.1007/s00259-021-05246-x | Alzheimer Disease* / diagnostic imaging Amyloid Amyloid beta-Peptides, Amyloidosis, Cognitive Dysfunction, Humans, Positron-Emission Tomography, tau Proteins , | |
| Molecular Imaging Approaches in Dementia | Villemagne | 2021 | AMYPAD | https://doi.org/10.1148/radiol.2020200028 | Dementia / diagnostic imaging* Disease Progression Early Diagnosis Humans Molecular Imaging, Neuroimaging, Positron-Emission Tomography, Prognosis, Radiopharmaceuticals, Tomography, Emission-Computed, Single-Photon , | |
| Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives | Cotta Ramusino | 2021 | AMYPAD | https://doi.org/10.1007/s00259-020-05187-x | Outcome, Clinical utility, Amyloid-PET, Diagnostic biomarkers, Alzheimer’s disease, Systematic review | |
| Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging | Lopes | 2021 | AMYPAD | https://doi.org/10.1186/s13195-021-00819-2 | PET imaging, Amyloid, Alzheimer’s disease, Prevention, Sample size, Clinical trial | |
| Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB | Heeman | 2021 | AMYPAD | https://doi.org/10.1007/s11307-021-01606-z | [11C]PiB, Alzheimer’s disease, Cerebral blood flow, Relative tracer delivery, Test-retest variability | |
| Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals | Collij | 2021 | AMYPAD | https://doi.org/10.1002/dad2.12216 | Alzheimer's disease, amyloid beta, longitudinal, positron emission tomography, regional | |
| Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease | Pfeil | 2021 | AMYPAD | https://doi.org/10.1016/j.neurobiolaging.2021.06.014 | Alzheimer's disease, Mild cognitive impairment, Regional amyloid burden, Positron emission tomography, Disease progression, Amyloid-beta | |
| Genetically identical twins show comparable tau PET load and spatial distribution | Coomans | 2022 | AMYPAD | https://doi.org/10.1093/brain/awac004 | Alzheimer’s disease, tau, PET, twins, genetics, alzheimer's disease, tau, proteins, monozygotic twins, genetics, pathology | |
| Spatial-Temporal Patterns of Amyloid-β Accumulation: A Subtype and Stage Inference Model Analysis | Colij | 2022 | AMYPAD | https://doi.org/10.1212/WNL.0000000000200148 | amyloid; occipital; subtypes; amyloid-PET; ALFA+, EMIF-AD, ABIDE, OASIS, ADNI; APOE; Alzheimer's disease, risk factors | |
| Should Doctors Offer Biomarker Testing to Those Afraid to Develop Alzheimer’s Dementia? | Smedinga | 2022 | AMYPAD | https://doi.org/10.1007/s11673-022-10185-9 | Bioethics, Alzheimer’s disease, Risk testing, Clinical ethics, Biomarkers | |
| Quantification of amyloid PET for future clinical use: a state-of-the-art review | Pemberton | 2022 | AMYPAD | https://doi.org/10.1007/s00259-022-05784-y | Brain, Amyloid, PET, Quantification, Alzheimer’s, Dementia, Centiloid, SUVr | |
| Impact of cerebral blood flow and amyloid load on SUVR bias | Heeman | 2022 | AMYPAD | https://doi.org/10.1186/s13550-022-00898-8 | Alzheimer’s disease, Amyloid PET, Cerebral blood flow, Quantification, SUVR bias | |
| Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study | Altomare | 2022 | AMYPAD | https://doi.org/10.1002/alz.12696 | Alzheimer's; PET; amyloid; dementia; memory clinic population; mild cognitive impairment; subjective cognitive decline. | |
| Regional associations of white matter hyperintensities and early cortical amyloid pathology | Lorenzini | 2022 | AMYPAD | https://doi.org/10.1093/braincomms/fcac150 | White matter hyperintensities, amyloid PET, regional associations, multivariate analysis, pre-dementia population | |
| Association of Alzheimer’s disease polygenic risk scores with amyloid accumulation in cognitively intact older adults | Luckett | 2022 | AMYPAD | https://doi.org/10.1186/s13195-022-01079-4 | Alzheimer’s disease; Amyloid-PET; F-PACK; Longitudinal study; Polygenic risk score. | |
| The Amyloid Imaging for the Prevention of Alzheimer’s Disease Consortium: A European collaboration with global impact | Colij | 2022 | AMYPAD | https://www.frontiersin.org/articles/10.3389/fneur.2022.1063598/abstract | Amyloid, Positron - emission tomography, Consortium, Alzheimer's disease, diagnosis, prognosis | |
| Analysis of Psychological Symptoms Following Disclosure of Amyloid–Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline | Caprioglio | 2023 | AMYPAD | https://doi.org/10.1001/jamanetworkopen.2022.50921 | patients, anxiety, disclosure, symptoms, depression, pet, outcomes, amyloid, | |
| Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial | Altomare | 2023 | AMYPAD | https://jamanetwork.com/journals/jamaneurology/fullarticle/2804755 |
| Title | Description | Type | Project | |
|---|---|---|---|---|
| Diagnostic and Prognostic study (DPMS) | The AMYPAD DPMS will select and follow-up a memory clinic population suspected of possible AD, focusing on those with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and dementia where AD is in the differential diagnosis (900 subjects in 3 strata: SCD plus, MCI, dementia possibly due to AD), to determine the usefulness of β-amyloid imaging with regards to diagnostic confidence, decision trees, change in diagnosis, and alterations between planned and actual patient management plans. There are 8 active sites, 617 reserach participants and 408 scans performed (Last update January 2020). For more information please visit: |
cohort-clinical-amypad-1 | AMYPAD | |
| Prognostic and Natural History study (PNHS) | The AMYPAD PNHS will select and follow-up a natural history population ranging from cognitively normal, through subjective cognitive decline (SCD) towards mild cognitive impairment (MCI) due to early AD to better understand the natural history of the early disease phases and to evaluate the value of quantitative PET amyloid imaging measures for predicting progression within an Alzheimer's disease risk probability spectrum based on quantitative PET amyloid imaging measures, with or without other biomarkers through an intimate collaboration with EPAD and other non-EPAD cohorts. There are 9 active sites, 2 parent cohorts, 378 research participants and 297 scans performed (Last update January 2020). For more information, please visit: https://amypad.eu/project/amypad-pnhs/ https://amypad.eu/wp-content/uploads/2019/11/AMYPAD-PNHS-Parent-Cohort-Data-Dictionary-v0.1.pdf |
cohort-clinical-amypad-2 | AMYPAD | |
| Neuroimaging datasets from the AMYPAD PNHS and DPMS studies | AMYPAD's PET and MRI imaging data set releases will be made available via collaborative workspaces. These data set releases will only include de-identified and cleaned data, from the Diagnostic and Patient Management Study (DPMS) and the Prognostic and Natural History Study (PNHS). Recruitment of the DPMS should be completed in 2020, with results expected in 2021. The data management activities have been started to ensure a clean dataset for the next step of data analysis. Recruitment of the PNHS is ongoing. The AMYPAD PNHS data will be made publicly available in the future. In line with the EPAD project, data locks will occur at least at V.1000, V.1500 and V.2000. Information on the PNHS data dictionary can be found here: https://amypad.eu/wp-content/uploads/2019/11/AMYPAD-PNHS-Parent-Cohort-Data-Dictionary-v0.1.pdf. For more information on the AMYPAD imaging datasets, please visit: |
dataset-clinical-amypad-9 | AMYPAD | |
| NiftyPET | "NiftyPET is an open source software solution for standalone and high-throughput PET image reconstruction and analysis. The key computational routines are written in CUDA C for fast and efficient processing on NVIDIA GPU devices. The routines are then embedded in Python C extensions to be readily available for high level programming in Python. The purpose of this software platform is to enable rapid processing of raw data as wells as image data for fully controlled quantitative PET image reconstruction and analysis. NiftyPET includes two stand-alone and independent Python packages: nipet and nimpa, which are dedicated to high-throughput image reconstruction and analysis. Strong emphasis is put on the data, which are acquired using positron emission tomography (PET) and magnetic resonance (MR), especially the hybrid and simultaneous PET/MR scanners." |
tools-clinical-amypad-16 | AMYPAD |
| Website: https://amypad.eu/ |
Back to list